Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01643278 · ClinicalTrials.gov registry record · Phase 1
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01643278: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01643278 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01643278, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of dasatinib when given together with ipilimumab in treating patients with gastrointestinal stromal tumors or other sarcomas that cannot be removed by surgery or have spread to other places in the body. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways by targeting certain cells. Giving dasatinib together with ipilimumab may be a better treatment for patients with gastrointestinal stromal tumors or other sarcomas.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Dasatinib
- BIOLOGICAL Ipilimumab
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01643278
The ClinicalTrials.gov registry entry for NCT01643278 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01643278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01643278 about?
NCT01643278 is a clinical study titled "Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic". This phase I trial studies the side effects and best dose of dasatinib when given together with ipilimumab in treating patients with gastrointestinal stromal tumors or other sarcomas that cannot be removed by surgery or have spread to other places in the body. Dasatinib may stop the growth of tumor ...
What is the current status of trial NCT01643278?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-07. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01643278?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dasatinib (DRUG), Ipilimumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01643278?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.